156 related articles for article (PubMed ID: 37313373)
1. Chemical Complementarity of Breast Cancer Resident, T-Cell Receptor CDR3 Domains and the Cancer Antigen, ARMC3, is Associated With Higher Levels of Survival and Granzyme Expression.
Pakasticali N; Chobrutskiy A; Patel DN; Hsiang M; Zaman S; Cios KJ; Blanck G; Chobrutskiy BI
Cancer Inform; 2023; 22():11769351231177269. PubMed ID: 37313373
[TBL] [Abstract][Full Text] [Related]
2. Chemical complementarity between tumor resident, T-cell receptor CDR3s and MAGEA3/6 correlates with increased melanoma survival: Potential relevance to MAGE vaccine auto-reactivity.
Eakins RA; Chobrutskiy A; Teer JK; Patel DN; Hsiang M; Huda TI; Zaman S; Sexton WJ; Coppola D; Falasiri S; Blanck G; Chobrutskiy BI
Mol Immunol; 2022 Oct; 150():58-66. PubMed ID: 35987136
[TBL] [Abstract][Full Text] [Related]
3. TRB CDR3-cancer testis antigen chemical complementarity scoring for identifying productive immune responses in renal cell carcinoma.
Hudock TR; Barker VR; Manley BJ; Chobrutskiy A; Chobrutskiy BI; Diaz MJ; Song JJ; Blanck G
Cancer Biomark; 2023; 38(1):103-110. PubMed ID: 37545223
[TBL] [Abstract][Full Text] [Related]
4. An immunoinformatics assessment of the cancer testis antigen, DDX53, as a potential early esophageal cancer antigen.
Cheng P; Cios KJ; Varkhedi M; Barker VR; Yeagley M; Chobrutskiy A; Chobrutskiy BI; Blanck G
Oncoscience; 2023; 10():59-66. PubMed ID: 37953875
[TBL] [Abstract][Full Text] [Related]
5. Chemical complementarity between immune receptor CDR3s and candidate cancer antigens correlating with reduced survival: evidence for outcome mitigation with corticosteroid treatments.
Patel AR; Patel DN; Tu YN; Yeagley M; Chobrutskiy A; Chobrutskiy BI; Blanck G
J Biomol Struct Dyn; 2023 Jul; 41(10):4632-4640. PubMed ID: 35538689
[TBL] [Abstract][Full Text] [Related]
6. High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer.
Chobrutskiy BI; Chobrutskiy A; Zaman S; Yeagley M; Huda TI; Blanck G
Mol Immunol; 2021 Jul; 135():247-253. PubMed ID: 33933816
[TBL] [Abstract][Full Text] [Related]
7. Erratum to "Chemical Complementarity of Breast Cancer Resident, T-Cell Receptor CDR3 Domains and the Cancer Antigen, ARMC3, is Associated With Higher Levels of Survival and Granzyme Expression".
Cancer Inform; 2023; 22():11769351231189051. PubMed ID: 37465006
[TBL] [Abstract][Full Text] [Related]
8. TCR CDR3-antigen chemical complementarity associated with poor ovarian cancer outcomes: A vestigial immune response to early cancer antigens?
Barker VR; Varkhedi M; Patel DN; Hsiang M; Chobrutskiy A; Chobrutskiy BI; Blanck G
Am J Reprod Immunol; 2023 Jan; 89(1):e13639. PubMed ID: 36317868
[TBL] [Abstract][Full Text] [Related]
9. A scoring system for the electrostatic complementarities of T-cell receptors and cancer-mutant amino acids: multi-cancer analyses of associated survival rates.
Chobrutskiy BI; Yeagley M; Diviney A; Zaman S; Gozlan EC; Tipping P; Koohestani DM; Roca AM; Blanck G
Immunology; 2020 Apr; 159(4):373-383. PubMed ID: 31821535
[TBL] [Abstract][Full Text] [Related]
10. Electrostatic Complementarities of Glioblastoma-Resident T-Cell Receptors and Cancer Testis Antigens Linked to Poor Outcomes and High Levels of Sphingosine Kinase-2 Expression.
Arias MA; Cios KJ; Kacsoh DB; Montgomery BE; Song JJ; Patel AR; Chobrutskiy A; Chobrutskiy BI; Blanck G
Biology (Basel); 2023 Apr; 12(4):. PubMed ID: 37106775
[TBL] [Abstract][Full Text] [Related]
11. Delineation of a T-cell receptor CDR3-cancer mutanome aromaticity factor, assessable via blood samples, that facilitates the establishment of survival distinctions in bladder cancer.
Waweru JW; Mwangi KW; Barker VR; Gozlan EC; Yeagley M; Blanck G; Makokha FW
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4359-4366. PubMed ID: 36098856
[TBL] [Abstract][Full Text] [Related]
12. IGL CDR3 Hydropathy and Antigen Chemical Complementarity Associated with Greater Disease-Free Survival in Lung Adenocarcinoma: Implications for Gender Disparities.
Charkowick SV; Huda TI; Patel DN; Yeagley M; Arturo JF; Cios KJ; Gozlan EC; Chobrutskiy A; Chobrutskiy BI; Blanck G
Biochem Genet; 2024 Feb; 62(1):530-546. PubMed ID: 37392243
[TBL] [Abstract][Full Text] [Related]
13. Chemical Complementarity of Tumor Resident, Adaptive Immune Receptor CDR3s and Previously Defined Hepatitis C Virus Epitopes Correlates with Improved Outcomes in Hepatocellular Carcinoma.
Song JJ; Chobrutskiy A; Chobrutskiy BI; Cios KJ; Huda TI; Eakins RA; Diaz MJ; Blanck G
Viral Immunol; 2023 Dec; 36(10):669-677. PubMed ID: 38052065
[TBL] [Abstract][Full Text] [Related]
14. Chemical complementarity between immune receptors and cancer mutants, independent of antigen presentation protein binding, is associated with increased survival rates.
Hsiang M; Chobrutskiy BI; Diaz M; Huda TI; Creadore S; Zaman S; Cios KJ; Gozlan EC; Blanck G
Transl Oncol; 2021 Jun; 14(6):101069. PubMed ID: 33780706
[TBL] [Abstract][Full Text] [Related]
15. TCR CDR3-CMV Antigen Chemical Complementaries Are Associated With a Worse Outcome for Renal Cell Carcinoma.
Alkassab L; Diaz MJ; Fetcher EA; Huda TI; Paul S; Kumar S; Chobrutskiy A; Chobrutskiy BI; Song JJ; Blanck G
Anticancer Res; 2024 Apr; 44(4):1505-1511. PubMed ID: 38537966
[TBL] [Abstract][Full Text] [Related]
16. Exploiting big data survival information to unify risk-stratification related, adaptive immune receptor parameters for multiple myeloma.
Wolmarans HJ; Barker VR; Chobrutskiy A; Chobrutskiy BI; Huda TI; Blanck G
Genes Immun; 2023 Aug; 24(4):194-199. PubMed ID: 37443300
[TBL] [Abstract][Full Text] [Related]
17. Electrostatic Complementarity of T-Cell Receptor-Alpha CDR3 Domains and Mutant Amino Acids Is Associated with Better Survival Rates for Sarcomas.
Yeagley M; Chobrutskiy BI; Gozlan EC; Medikonda N; Patel DN; Falasiri S; Callahan BM; Huda T; Blanck G
Pediatr Hematol Oncol; 2021 Apr; 38(3):251-264. PubMed ID: 33616477
[TBL] [Abstract][Full Text] [Related]
18. Blood-based T cell receptor anti-viral CDR3s are associated with worse overall survival for neuroblastoma.
Kacsoh DB; Diaz MJ; Gozlan EC; Sahoo A; Song JJ; Yeagley M; Chobrutskiy A; Chobrutskiy BI; Blanck G
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12047-12056. PubMed ID: 37421457
[TBL] [Abstract][Full Text] [Related]
19. T-cell receptor-α CDR3 domain chemical features correlate with survival rates in bladder cancer.
Chobrutskiy BI; Zaman S; Diviney A; Mihyu MM; Blanck G
J Cancer Res Clin Oncol; 2019 Mar; 145(3):615-623. PubMed ID: 30539280
[TBL] [Abstract][Full Text] [Related]
20. Specific TCR V-J gene segment recombinations leading to the identification pan-V-J CDR3s associated with survival distinctions: diffuse large B-cell lymphoma.
Cios KJ; Huda TI; Eakins RA; Mihyu MM; Blanck G
Leuk Lymphoma; 2022 Jun; 63(6):1314-1322. PubMed ID: 35019822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]